NRx Pharmaceuticals (NRXP) Scheduled to Post Earnings on Tuesday

NRx Pharmaceuticals (NASDAQ:NRXP) will be posting its quarterly earnings results after the market closes on Tuesday, May 14th.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings data on Friday, March 29th. The company reported ($0.50) EPS for the quarter.

NRx Pharmaceuticals Trading Down 2.8 %

Shares of NRXP traded down $0.08 on Wednesday, reaching $2.73. The company’s stock had a trading volume of 99,821 shares, compared to its average volume of 308,214. The stock has a market capitalization of $28.83 million, a PE ratio of -0.70 and a beta of 1.15. NRx Pharmaceuticals has a twelve month low of $1.90 and a twelve month high of $12.00. The firm has a fifty day moving average of $26.62 and a 200-day moving average of $34.35.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.